Canada markets closed

PFE Jun 2023 50.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
5.35+1.00 (+22.99%)
As of 03:16PM EDT. Market open.
Full screen
Loading interactive chart...
  • Editor's Pick
    Yahoo Finance

    Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity

    Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

  • Reuters

    Biotech stocks pin bounce back hopes on M&A boost

    Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner. Pfizer's $5.4 billion acquisition of Global Blood Therapeutics, which was announced on Monday, is the fourth deal in the sector since the pharma giant bought Biohaven for $11.6 billion in May, adding to optimism that large drugmakers are back in the market to pick up cheaper firms. Industry experts predict biotech firms that are closer to getting their product to market or already have a drug approved are likely to become M&A targets for large drugmakers, some of whom are staring at patent expirations of their cash cow drugs.

  • Zacks

    Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023

    Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.